Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition.
Apoptosis is recognized as important for normal cellular homeostasis in multicellular organisms. Although there have been great advances in our knowledge of the molecular events regulating apoptosis, much less is known about the receptors on phagocytes responsible for apoptotic cell recognition and phagocytosis or the ligands on apoptotic cells mediating such recognition. The observations that apoptotic cells are under increased oxidative stress and that oxidized low-density lipoprotein (OxLDL) competes with apoptotic cells for macrophage binding suggested the hypothesis that both OxLDL and apoptotic cells share oxidatively modified moieties on their surfaces that serve as ligands for macrophage recognition. To test this hypothesis, we used murine monoclonal autoantibodies that bind to oxidation-specific epitopes on OxLDL. In particular, antibodies EO6 and EO3 recognize oxidized phospholipids, including 1-palmitoyl 2-(5-oxovaleroyl) phosphatidylcholine (POVPC), and antibodies EO12 and EO14 recognize malondialdehyde-lysine, as in malondialdehyde-LDL. Using FACS analysis, we demonstrated that each of these EO antibodies bound to apoptotic cells but not to normal cells, whereas control IgM antibodies did not. Confocal microscopy demonstrated cell-surface expression of the oxidation-specific epitopes on apoptotic cells. Furthermore, each of these antibodies inhibited the phagocytosis of apoptotic cells by elicited peritoneal macrophages, as did OxLDL. In addition, an adduct of POVPC with BSA also effectively prevented phagocytosis. These data demonstrate that apoptotic cells express oxidation-specific epitopes-including oxidized phospholipids-on their cell surface, and that these serve as ligands for recognition and phagocytosis by elicited macrophages.
Chang
M K
MK
Department of Medicine 0682, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0682, USA.
Bergmark
C
C
Laurila
A
A
Hörkkö
S
S
Han
K H
KH
Friedman
P
P
Dennis
E A
EA
Witztum
J L
JL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology*; D000918:Antibody Specificity; D001011:Aorta; D017209:Apoptosis; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology* / Q000502:physiology*; D000939:Epitopes / Q000276:immunology; D005434:Flow Cytometry; D007075:Immunoglobulin M / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000502:physiology*; D051379:Mice; D010587:Phagocytosis / Q000502:physiology*; D010713:Phosphatidylcholines / Q000276:immunology; D013552:Swine; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology
C119546:1-palmitoyl-2-(5-oxovaleroyl)phosphatidylcholine; D000911:Antibodies, Monoclonal; D000939:Epitopes; D007075:Immunoglobulin M; D008077:Lipoproteins, LDL; D010713:Phosphatidylcholines; C099252:oxidized low density lipoprotein; D003907:Dexamethasone